SELLAS Life Sciences (SLS) Accumulated Depreciation & Amortization (2010 - 2017)
SELLAS Life Sciences (SLS) reported Accumulated Depreciation & Amortization of $26000.0 for Q1 2017, up 333.33% year-over-year from $6000.0 in Q1 2016, and down 81.69% on a QoQ basis from $142000.0 in Q4 2016.
SELLAS Life Sciences (SLS) has 7 years of Accumulated Depreciation & Amortization data on file, last reported at $26000.0 in Q1 2017.
- Quarterly Accumulated Depreciation & Amortization rose 333.33% year-over-year to $26000.0 in Q1 2017, while the trailing twelve-month figure through Mar 2017 was $26000.0 (up 333.33% YoY) and the FY2016 annual result came in at $142000.0, up 32.71% from the prior year.
- Accumulated Depreciation & Amortization slipped to $26000.0 in Q1 2017 per SLS's latest filing, from $142000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $1.4 million in Q3 2016 and bottomed at $6000.0 in Q1 2016.
- The 5-year median for Accumulated Depreciation & Amortization is $161500.0 (2015), against an average of $310666.7.
- Peak annual rise in Accumulated Depreciation & Amortization reached 352.3% in 2016, while the deepest fall reached 93.88% in 2016.
- Tracing SLS's Accumulated Depreciation & Amortization over 5 years: stood at $286000.0 in 2013, then plunged by 69.93% to $86000.0 in 2014, then advanced by 24.42% to $107000.0 in 2015, then surged by 32.71% to $142000.0 in 2016, then tumbled by 81.69% to $26000.0 in 2017.
- Per Business Quant, the three latest SLS Accumulated Depreciation & Amortization figures stand at $26000.0 (Q1 2017), $142000.0 (Q4 2016), and $1.4 million (Q3 2016).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 26,000.00 |
| Mar 31, 2017 | 26,000.00 |
| Dec 31, 2016 | 142,000.00 |
| Dec 31, 2016 | 142,000.00 |
| Sep 30, 2016 | 1.38 Mn |
| Sep 30, 2016 | 1.38 Mn |
| Jun 30, 2016 | 777,000.00 |
| Jun 30, 2016 | 777,000.00 |
| Mar 31, 2016 | 6,000.00 |
| Mar 31, 2016 | 6,000.00 |
| Dec 31, 2015 | 107,000.00 |
| Dec 31, 2015 | 107,000.00 |
| Sep 30, 2015 | 304,000.00 |
| Sep 30, 2015 | 304,000.00 |
| Jun 30, 2015 | 181,000.00 |
| Jun 30, 2015 | 181,000.00 |
| Mar 31, 2015 | 98,000.00 |
| Mar 31, 2015 | 98,000.00 |
| Dec 31, 2014 | 86,000.00 |
| Dec 31, 2014 | 86,000.00 |
| Sep 30, 2014 | 340,000.00 |
| Sep 30, 2014 | 340,000.00 |
| Dec 31, 2013 | 286,000.00 |
| Dec 31, 2013 | 286,000.00 |
| Dec 31, 2011 | 163,000.00 |
| Dec 31, 2011 | 163,000.00 |
| Dec 31, 2010 | 172,000.00 |
| Dec 31, 2010 | 172,000.00 |